PellePharm announces launch to develop topical gel for basal cell carcinoma

PellePharm announced its launch today, with financing from BridgeBio Pharma. The Menlo Park, Calif.-based company is developing a topical gel to treat basal cell carcinoma, including the tumors that result from Gorlin syndrome. The company’s topical inhibitor compound, patidegib, acts on the hedgehog pathway – a signaling pathway that transmits cellular information for adult tissue maintenance. Abnormal hedgehog signaling has been correlated with a number of cancers including basal cell carcinoma. PellePharm is studying the topical formulation of patidegib in 2 phase II trials. A study evaluating the gel’s use in patients with Gorlin syndrome just completed enrollment, according to the company. Get the full story at our sister site,┬áDrug Delivery Business News. The post PellePharm announces launch to develop topical gel for basal cell carcinoma appeared first on MassDevice.
Source: Mass Device - Category: Medical Equipment Authors: Tags: Clinical Trials Drug-Device Combinations Oncology Pharmaceuticals BridgeBio Pharma PellePharm Source Type: news